Puma Biotechnology, Inc. Prevails Before European Patent Office Board of Appeals in Decision Upholding European Patent (EP 1848414) as Granted

Puma Biotechnology, Inc. Prevails Before European Patent Office Board of Appeals in Decision Upholding European Patent (EP 1848414) as Granted

LOS ANGELES–(BUSINESS WIRE)–
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that it has prevailed in final appeal proceedings brought against its licensed European patent EP Patent 1848414, which covers the use of irreversible EGFR inhibitors in treating gefitinib and/or erlotinib resistant cancer and cancer with a T790M EGFR mutation. The European Board of Appeals announced its decision at a hearing on December 1st, rejecting the opposition of EP Patent 1848414 initiated by a Boehringer Ingelheim entity.

The EP Patent 1848414 originally granted in April 2011 covers the use of irreversible EGFR inhibitors in treating gefitinib and/or erlotinib resistant cancer and cancer with a T790M EGFR mutation. On November 28, 2011, an opposition was filed seeking invalidation of the patent. The Opposition Division of the European Patent Office issued a decision on February 4, 2014 revoking some claims but upheld a subset of the granted claims relating to a pharmaceutical composition for use in treating cancer in a subject having a T790M EGFR mutation without any modification. Both parties appealed that decision in 2017. At a final hearing, the Board of Appeals announced its decision, concluding that the opposition was inadmissible and reversing the European Opposition Division decision issued in 2014, thereby upholding the EP Patent 1848414 as originally granted.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX® (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Further information about Puma Biotechnology may be found at www.pumabiotechnology.com.

Alan H. Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500

[email protected]

[email protected]

David Schull or Maggie Beller, Russo Partners, +1 212 845 4200

[email protected]

[email protected]

KEYWORDS: California Europe United States North America

INDUSTRY KEYWORDS: Biotechnology Pharmaceutical Health Oncology

MEDIA:

Logo
Logo

Silo Pharma Announces Plans for a Phase 2B Investigator Lead Study Using Psychedelics Psilocybin and Lysergic Acid Diethylamide (“LSD”) to Treat Parkinson’s Disease

Silo Pharma Announces Plans for a Phase 2B Investigator Lead Study Using Psychedelics Psilocybin and Lysergic Acid Diethylamide (“LSD”) to Treat Parkinson’s Disease

Collaboration with the University of Maastricht of the Netherlands

TEANECK, N.J.–(BUSINESS WIRE)–
Silo Pharma, Inc. (OTCQB: SILO), a developmental stage biopharmaceutical company focused on the use of psilocybin as a therapeutic, today announced that it has entered into an investigator-sponsored study agreement with Maastricht University of the Netherlands. The research project is a clinical study to examine the effects of repeated low doses of psilocybin and LSD on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action.

Dr. Kim Kuypers, Associate Professor, Department of Neuropsychology and Psychopharmacology at Maastricht University, will serve as Investigator Sponsor for the Phase 2B study. Dr. Kuypers’ main topics of interest are MDMA and psychedelics and their effects on (social) cognition, creativity, hormones, and underlying brain mechanisms.

“The signing of this clinical study agreement represents a significant milestone for the Company as we continue our work to bring novel therapeutics to patients in need,” stated Eric Weisblum, Chairman and CEO of Silo Pharma. “Dr. Kuypers is one of the world’s foremost clinical investigators in the field of psychedelics and has previously evaluated the concept of micro-dosing in her research.”

The Phase 2B study is a human study to be conducted on a sufficient number of patients, the primary purpose of which is to evaluate the safety and efficacy of psilocybin and LSD on patients suffering from Parkinson’s disease. The primary objective of this trial is to investigate the effects of repeated low doses of psilocybin and LSD on well-being and affect (self-rated), emotional and cognitive attention (computer tasks), and biological markers of neuroplasticity. Secondary objectives are to investigate the effects of repeated low doses of psilocybin and LSD on cognitive performance measures of memory and executive functioning, known to be impaired in Parkinson’s disease (computer tasks) and emotion regulation Parkinson’s symptoms, and biological markers of well-being (immune system, cortisol).

“Parkinson’s disease is a progressive nervous system disorder that affects 7-10 million people globally and currently has no cure,” added Mr. Weisblum. “Our goal, in collaborating with Maastricht University and Dr. Kuypers, is to bring hope to those suffering with this terrible disease. We expect to share additional information regarding protocol, ethics submission and initiation of the study as the information becomes available.”

About Silo Pharma

Silo Pharma, Inc. is a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research for people suffering from indications such as depression, PTSD, Parkinson’s, and other rare neurological disorders. Silo’s mission is to identify assets to license and fund the research which we believe will be transformative to the well-being of patients and the health care industry. For more information, visit www.silopharma.com.

Safe Harbor and Forward-Looking Statements

This news release contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are identified by the use of words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “may,” “continue,” “predict,” “potential” and similar expressions that are intended to identify forward-looking statements. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of Silo Pharma, Inc. (“Silo” or “the Company”) to differ materially from the results expressed or implied by such statements, including changes to anticipated sources of revenues, future economic and competitive conditions, difficulties in developing the Company’s technology platforms, retaining and expanding the Company’s customer base, fluctuations in consumer spending on the Company’s products and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company disclaims any obligations to publicly update or release any revisions to the forward-looking information contained in this presentation, whether as a result of new information, future events or otherwise, after the date of this presentation or to reflect the occurrence of unanticipated events except as required by law.

Investor Relations Contact:

Hayden IR

Brett Maas

646-536-7331

Email: [email protected]

KEYWORDS: Netherlands Europe

INDUSTRY KEYWORDS: Mental Health Health Clinical Trials Research Science Pharmaceutical Biotechnology

MEDIA:

Clean Harbors to Present at BMO Capital Markets 2020 Growth & ESG Conference

Clean Harbors to Present at BMO Capital Markets 2020 Growth & ESG Conference

NORWELL, Mass.–(BUSINESS WIRE)–Clean Harbors, Inc. (“Clean Harbors”) (NYSE: CLH) the leading provider of environmental and industrial services throughout North America, today announced that Chief Financial Officer Michael L. Battles, EVP Corporate Planning and Development Brian P. Weber and SVP Investor Relations Jim Buckley will be participating in a fireside chat at the BMO Capital Markets 2020 Growth & ESG Conference.

Clean Harbors’ presentation will take place at 2:00 p.m. ET on Tuesday, December 8, and will be webcast live. To access the live or archived webcast, visit the “Investor Relations” portion of Clean Harbors’ website at www.cleanharbors.com.

About Clean Harbors

Clean Harbors (NYSE: CLH) is North America’s leading provider of environmental and industrial services. The Company serves a diverse customer base, including a majority of Fortune 500 companies. Its customer base spans a number of industries, including chemical, energy and manufacturing, as well as numerous government agencies. These customers rely on Clean Harbors to deliver a broad range of services such as end-to-end hazardous waste management, emergency spill response, industrial cleaning and maintenance, and recycling services. Through its Safety-Kleen subsidiary, Clean Harbors also is North America’s largest re-refiner and recycler of used oil and a leading provider of parts washers and environmental services to commercial, industrial and automotive customers. Founded in 1980 and based in Massachusetts, Clean Harbors operates in the United States, Canada, Mexico, Puerto Rico and India. For more information, visit www.cleanharbors.com.

Michael L. Battles

EVP and Chief Financial Officer

Clean Harbors, Inc.

781.792.5100

[email protected]

Jim Buckley

SVP Investor Relations

Clean Harbors, Inc.

781.792.5100

[email protected]

KEYWORDS: Massachusetts United States North America

INDUSTRY KEYWORDS: Energy Environment Oil/Gas

MEDIA:

Logo
Logo

NeoPhotonics Announces New Class 60 Coherent Modulator and Class 60 Coherent Receiver for 100+ Gbaud Symbol Rates Enabling 800G and Above Per Wavelength Applications

NeoPhotonics Announces New Class 60 Coherent Modulator and Class 60 Coherent Receiver for 100+ Gbaud Symbol Rates Enabling 800G and Above Per Wavelength Applications

NeoPhotonics Provides a Complete Optical Solution for 800Gbps and Above Data Rates for Single Wavelength Transmission when Combined with NeoPhotonics Ultra-Narrow Linewidth Nano-Tunable Laser

SAN JOSE, Calif.–(BUSINESS WIRE)–
NeoPhotonics Corporation (NYSE: NPTN), a leading developer of silicon photonics and advanced hybrid photonic integrated circuit-based lasers, modules and subsystems for bandwidth-intensive, high speed communications networks, today announced the addition of Class 60 versions of its Coherent Driver-Modulator (CDM) and Intradyne Coherent Receiver (Micro-ICR) to its suite of High Bandwidth Coherent components, addressing the next generation of 100+ Gbaud systems to meet the ongoing growth in demand for bandwidth, especially between cloud data centers. Optical performance improvement due to increased baud rates enables NeoPhotonics customers to pack more data over longer distances for better economics, lower cost per bit, lower operating expenses and lower power consumption, all under the same hardware envelope as they currently enjoy using NeoPhotonics Class 40 components.

These new Class 60 Coherent components extend the highest speed over distance performance of our existing Class 50 products by increasing the 3 dB bandwidth from 50 GHz to 60 GHz. The Class 60 suite improves on the currently shipping Class 40 components, and allows increasing symbol rates from the current 64+ Gbaud rate to the higher 100+ Gbaud rates. These NeoPhotonics components work together to enable customers to implement single wavelength data transmission near one Terabit per second over datacenter interconnect (DCI) distances, and long-haul 400~500Gbps transmission.

Higher symbol rates increase data capacity while maintaining superior optical signal to noise ratio (OSNR) and reach performance, thereby enabling the highest speed over distance use. These new components are available in compact form factor packages suitable for use in pluggable modules and compact daughter cards. NeoPhotonics Class 60 CDM and Micro-ICR are mechanically compatible to their Class 40 counterparts, and are a natural upgrade path for achieving the higher symbol rates (100+ Gbaud) in order to support 800Gbps and above data rates per wavelength applications.

The Class 60 suite comprises:

  • Class 60 CDM: NeoPhotonics Class 60, polarization multiplexed, coherent driver modulator (CDM) features a co-packaged InP modulator with four linear, high bandwidth, differential drivers, and is designed for low V-Pi, low insertion loss and a high extinction ratio. The compact package is designed to be compliant with the form factor of the OIF Implementation Agreement #OIF-HB-CDM-01.0.
  • Class 60 Micro-ICR: NeoPhotonics Class 60 High Bandwidth Micro-Intradyne Coherent Receiver (Micro-ICR) is designed for 100+ Gbaud symbol rates, more than tripling the rate of standard 100G ICRs. The compact package is designed to be compliant with the OIF Implementation Agreement OIF-DPC-MRX-02.0.

These components are designed to work together with NeoPhotonics “Nano” ultra-narrow linewidth external cavity tunable laser, which cuts the size approximately in half compared to current Micro-ITLAs, while featuring industry leading linewidth and low phase noise with low electrical power consumption.

“NeoPhotonics has supported our customers by being first to volume production of our products at each new speed node. We are pleased to now offer Class 60 coherent modulators and receivers, which along with our ultra-narrow linewidth external cavity “nano” tunable laser, provide a complete suite of components enabling customers to increase the data rate per wavelength to one Terabit and beyond,” said Tim Jenks, Chairman and CEO of NeoPhotonics. “We are continuing to extend the bandwidth of our Indium Phosphide coherent integration platform to serve the highest speed over distance applications,” concluded Mr. Jenks.

About NeoPhotonics

NeoPhotonics is a leading developer and manufacturer of lasers and optoelectronic solutions that transmit, receive and switch high-speed digital optical signals for Cloud and hyper-scale data center internet content provider and telecom networks. The Company’s products enable cost-effective, high-speed over distance data transmission and efficient allocation of bandwidth in optical networks. NeoPhotonics maintains headquarters in San Jose, California and ISO 9001:2015 certified engineering and manufacturing facilities in Silicon Valley (USA), Japan and China. For additional information visit www.neophotonics.com.

Legal Notice Regarding Forward-Looking Statements

This press release includes statements that qualify as forward-looking statements under the Private Securities Litigation Reform Act of 1995, including anticipated performance of NeoPhotonics’ products. Readers are cautioned that these forward-looking statements involve risks and uncertainties and are only predictions based on the company’s current expectations, estimates and projections. The actual company results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks, uncertainties and assumptions. Certain risks and uncertainties that could cause the company’s results to differ materially from those expressed or implied by such forward-looking statements as well as other risks and uncertainties relating to the company’s business, are described more fully in the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 and its Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, filed with the Securities and Exchange Commission.

©2020 NeoPhotonics Corporation. All rights reserved. NeoPhotonics and the red dot logo are trademarks of NeoPhotonics Corporation. All other marks are the property of their respective owners.

NeoPhotonics Contact:

LouVan Communications, Inc.

Michael Newsom

Mobile: +1 617-803-5385

Email: [email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Telecommunications Networks Nanotechnology Internet Hardware Data Management Technology Semiconductor

MEDIA:

Logo
Logo

Stratasys Enhances Digital Anatomy 3D Printer to Bring Ultra-Realistic Simulation and Realism to Functional Bone Models

Stratasys Enhances Digital Anatomy 3D Printer to Bring Ultra-Realistic Simulation and Realism to Functional Bone Models

New research studies verify the biomechanical accuracy of 3D-printed orthopedic models

EDEN PRAIRIE, Minn. & REHOVOT, Israel–(BUSINESS WIRE)–
3D printing leader Stratasys Ltd. (NASDAQ: SSYS) has enhanced its J750 Digital Anatomy™ 3D printer with advanced bone capabilities that don’t just look real but are actually biomechanically realistic, backed by clinical research. The software upgrade enables the systems to mimic porous bone structures, fibrotic tissue, and ligaments so medical professionals can create models that behave just like human bone.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201202005096/en/

The Digital Anatomy 3D printer from Stratasys enables physicians to practice inserting screws for orthopedic applications with biomechanical realism similar to a human anatomy. (Photo: Business Wire)

The Digital Anatomy 3D printer from Stratasys enables physicians to practice inserting screws for orthopedic applications with biomechanical realism similar to a human anatomy. (Photo: Business Wire)

The Digital Anatomy printer was first introduced a year ago, with an initial focus on mimicking soft cardiology tissues, such as hearts and blood vessels, using powerful Digital Anatomy software and materials like GelMatrix™ and TissueMatrix™. The technology has helped healthcare providers improve surgical preparedness and medical device makers to conduct testing and train medical professionals on new devices. BoneMatrix™ material with the enhanced software capabilities extends those benefits to orthopedic applications.

“We believe that better preparation leads to better clinical outcomes,” said Vice President Osnat Philipp, who leads the global healthcare team at Stratasys. “The mechanical properties of bone are so fundamental to the ability of our skeletons to support movement, provide protection for our vital organs and ultimately affect our quality of life. Being able to 3D print models that are biomechanically accurate and unique to each patient is critical to that preparation.”

Despite the high demand for bone models, traditional model options have serious shortcomings. The medical industry has traditionally used human bone from cadavers, or legacy 3D printing solutions, all of which have proven inadequate. Human bone is expensive, difficult to obtain, and hard to acquire with the precise pathology characteristics needed, such as with tumors or reflecting different ages. Off-the-shelf manufactured bone models also lack those patient-specific characteristics, and other traditional 3D printing solutions are biomechanically unrealistic. In contrast, whether inserting a screw or drilling or sawing a bone, medical professionals can expect haptic feedback from Digital Anatomy models that is very realistic, and each model can be created from an actual patient scan.

3D-printed skull and spine models for physician training workshops allow doctors to practice cutting and drilling bones, said a medical director at a children’s hospital in Florida. Her focus has been on using state-of-the-art simulation to transform pediatric training and education. “The opportunities seem endless to me because doctors can ‘operate before they operate,’” she said. “It’s going to decrease surgical time, it’s going to decrease morbidity and mortality, and help us decrease anesthesia time, which is better for brain development.”

While the 3D printer itself is cutting-edge technology, it’s the Digital Anatomy software that unlocks its power. More than 100 sophisticated presets have been developed and refined through years of expert testing, in partnership with top academic medical centers and hospitals around the world. For example, intervertebral discs can be printed normal or degenerated. The joints between vertebrae can be printed in varying degrees of stiffness. The denser structure of skull bone is differentiated from general bones. Long bones can be printed with varying amounts of marrow. Different combinations of materials are produced at a 3D voxel level to ensure the right biomechanical properties.

Researchers at the Computational Mechanics and Experimental Biomechanics Lab at Tel Aviv University conducted a clinical evaluation of the characteristics of bone models that were 3D printed on the Digital Anatomy system, specifically focusing on how accurately they replicated screw pull-out force and driving torque using cortical and cancellous screws. The 2020 study concluded that orthopedic screws pull-out force in the 3D-printed models had a similar haptic response to human cadaver bone.

A second study conducted this year by researchers at the Technion Institute of Technology’s Materials Science and Engineering Laboratory in Israel demonstrated the mechanical accuracy of 3D-printed spine models compared to cadaver spines. The study was able to demonstrate that the 3D-printed models of lumbar vertebrae accurately represented the range of motion compared to published literature on human spines.

More information on the Digital Anatomy 3D printer is available online.

Stratasys is a global leader in additive manufacturing or 3D printing technology and is the manufacturer of FDM®, PolyJet™, and stereolithography 3D printers. The company’s technologies are used to create prototypes, manufacturing tools, and production parts for industries, including aerospace, automotive, healthcare, consumer products and education. For more than 30 years, Stratasys products have helped manufacturers reduce product-development time, cost, and time-to-market, as well as reduce or eliminate tooling costs and improve product quality. The Stratasys 3D printing ecosystem of solutions and expertise includes 3D printers, materials, software, expert services, and on-demand parts production. Online at: www.stratasys.com.

To learn more about Stratasys, visit www.stratasys.com, the Stratasys blog, Twitter, LinkedIn, or Facebook. Stratasys reserves the right to utilize any of the foregoing social media platforms, including the company’s websites, to share material, non-public information pursuant to the SEC’s Regulation FD. To the extent necessary and mandated by applicable law, Stratasys will also include such information in its public disclosure filings.

Stratasys, PolyJet Technology, Digital Anatomy, BoneMatrix, GelMatrix, and TissueMatrix are trademarks of StratasysLtd. and/or its affiliates. All other trademarks are the property of their respective owners, and Stratasys assumes no responsibility with regard to the selection, performance, or use of these non-Stratasys products.

Attention Editors, if you publish reader-contact information, please use:

  • USA +800-801-6491
  • Europe/Middle East/Africa +49-7229-7772-0
  • Asia Pacific +852 3944-8888

 

Media Contacts

Stratasys Corporate & North America

Aaron Pearson

[email protected]

+1 612-716-9228

Investor Relations

Yonah Lloyd

[email protected]

+972-74-745-4919

Europe, Middle East, and Africa

Jonathan Wake / Miguel Afonso, Incus Media

[email protected]

+44 1737 215200

Brazil, Central America and South America

[email protected]

+55 (11) 2626-9229

Asia Pacific and Japan

Alice Chiu

[email protected]

+852-9189-7273

KEYWORDS: Minnesota United States North America Israel Middle East

INDUSTRY KEYWORDS: Other Health Software Research Hardware Medical Devices Technology Other Manufacturing Science Surgery Biotechnology Manufacturing Health

MEDIA:

Logo
Logo
Photo
Photo
The Digital Anatomy 3D printer from Stratasys enables physicians to practice inserting screws for orthopedic applications with biomechanical realism similar to a human anatomy. (Photo: Business Wire)
Photo
Photo
The Digital Anatomy 3D printer from Stratasys produces accurate models of patient bones down to the voxel level, including marrow, and even lets doctors include features like tumors. (Photo: Business Wire)

Emilie Hungenberg Joins AXIS Re as Senior Underwriter, Property, EMEA & Latin America

Emilie Hungenberg Joins AXIS Re as Senior Underwriter, Property, EMEA & Latin America

PEMBROKE, Bermuda–(BUSINESS WIRE)–
AXIS Re, the reinsurance business segment of AXIS Capital Holdings Limited (“AXIS Capital”) (NYSE:AXS), today announced that Emilie Hungenberg has joined AXIS Re as a Senior Underwriter, Property, EMEA & Latin America.

In this role, Ms. Hungenberg will be responsible for underwriting a Property treaty portfolio for France, Benelux, Iberia and Africa. She will work in partnership with the underwriting team responsible for these regions to further develop and execute AXIS Re’s underwriting strategy.

“We are delighted to welcome Emilie to AXIS Re,” said Gino Smith, Head of Property, EMEA & Latin America at AXIS Re. “She brings a strong technical underwriting background spanning short and long tail lines of business, as well as an extensive commercial network throughout the region. Emilie’s experience and expertise will further enable us to deliver on AXIS Re’s promise of providing agile, solution-oriented services to our clients and brokers.”

Ms. Hungenberg joins AXIS Re from investment manager Schroders, where she was a Senior ILS Underwriter and Project Manager, responsible for underwriting collateralized reinsurance for Europe, Bermuda and Lloyds. Prior to Schroders, Ms. Hungenberg held progressively senior roles in underwriting and client management with RMS, MS Amlin, Sompo and Odyssey Re.

Ms. Hungenberg will be based in Zurich and report directly to Mr. Smith.

About AXIS Capital

AXIS Capital, through its operating subsidiaries, is a global provider of specialty lines insurance and treaty reinsurance with shareholders’ equity at September 30, 2020 of $5.3 billion and locations in Bermuda, the United States, Europe, Singapore, Canada and the Middle East. Its operating subsidiaries have been assigned a rating of “A+” (“Strong”) by Standard & Poor’s and “A” (“Excellent”) by A.M. Best. For more information about AXIS Capital, visit our website at www.axiscapital.com. Follow AXIS Capital on LinkedIn and Twitter.

Investor Contact

Matt Rohrmann

AXIS Capital Holdings Limited

[email protected]

(212) 940-3339

Media Contact

Anna Kukowski

AXIS Capital Holdings Limited

[email protected]

(212) 715-3574

KEYWORDS: Europe Caribbean United Kingdom Bermuda

INDUSTRY KEYWORDS: Professional Services Insurance Finance

MEDIA:

Logo
Logo

AgJunction Announces Supply Agreement with New OEM Customer, Ploeger

SCOTTSDALE, Ariz., Dec. 02, 2020 (GLOBE NEWSWIRE) — AgJunction Inc. (TSX: AJX) (“AgJunction” or the “Company”) announced today that it has signed a supply agreement with a new Dutch OEM customer, Ploeger Oxbo Group BV (“Ploeger”) to provide auto steering systems for their CM4240 self-propelled silage merging device.

In anticipation of the partnership with AgJunction, Ploeger has integrated AgJunction’s autosteering hardware and software models in this new silage merging device. Based on the success of this first integration, AgJunction and Ploeger are exploring expanding autosteering to additional vehicles.

“Ploeger was able to quickly integrate our autosteering module through our customer API,” said Luke McBeath, AgJunction’s Senior Director of Engineering. “Our customer API will allow them to continue to improve functionality and user experience.”

“AgJunction’s autosteer system was easy for us to integrate into our new CM4240 silage merging device,” said Niels Havermans, Ploeger’s CCO. “We are excited to offer autosteering in our CM4240, which will improve the functionality of the vehicle and provide drivers with increased comfort. We are testing the autosteering system this season and expect to have a commercial version available for several of our machines in Q2 2021.”

M. Brett McMickell, AgJunction’s President and CEO, said of the new signing, “Ploeger’s rapid adoption of AgJunction’s autosteering system demonstrates the strength of our refined strategy. AgJunction provides the flexibility needed for manufacturers to rapidly integrate proven automation consistent with their unique strategies that accelerates the speed to market.”

About AgJunction

AgJunction Inc. is a global leader of advanced guidance and autosteering solutions for precision agriculture applications. Its technologies are critical components in over 30 of the world’s leading precision Ag manufacturers and solution providers and it holds over 200 patents and patents pending. AgJunction markets its solutions under leading brand names including Novariant®, Wheelman®, Whirl™ and Handsfreefarm® and is committed to advancing its vision by bringing affordable hands-free farming to every farm, regardless of terrain or size. AgJunction is headquartered in Scottsdale, Arizona, and is listed on the Toronto Stock Exchange (TSX) under the symbol “AJX.” For more information, please go to AgJunction.com.

About The Ploeger Oxbo Group

Ploeger Oxbo Group develops and manufactures a wide range of specialised agricultural equipment. These brands The Bourgoin, Oxbo and Ploeger brands have their roots in harvesters for vegetables, corn, fruit and root crops. More recently the product range has been extended with fertilizer spreaders and sprayers, industrial applicators and forage equipment.
The equipment is manufactured at seven locations in Europe, the US and Brazil and is sold through the company’s own branch offices, dealers and agents in 40 countries on all continents.
The Ploeger Oxbo Group employs 700 staff and has an annual turnover of over 200 million euros. The head office is located in Roosendaal, the Netherlands.

Forward-Looking Statements

This press release contains forward-looking information and forward-looking statements (collectively, “forward-looking information”) within the meaning of applicable securities laws and is based on the expectations, estimates and projections of management of AgJunction as of the date of this news release, unless otherwise stated. The use of any of the words “expect”, “anticipate”, “continue”, “estimate”, “objective”, “ongoing”, “may”, “will”, “project”, “should”, “believe”, “plans”, “intends” and similar expressions are intended to identify forward-looking information. These statements are only predictions and actual events or results may differ materially. Although the Company’s management believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee future results, performance or achievement since such expectations are inherently subject to significant business, economic, competitive and political uncertainties and contingencies. In particular, forward-looking statements in this press release include, but are not limited to statements with respect to: the Company’s vision with respect to autosteering for farmers and the expectation that regular updates will be pushed out to the app ensuring farmers can always operate their Wheelman products with the most up-to-date technology. Accordingly, readers should not place undue reliance on such forward-looking information contained in this press release.

In respect of the forward-looking information, AgJunction has provided such information in reliance on certain assumptions that it believes are reasonable at this time, including, but not limited to, the sufficiency of budgeted capital expenditures in carrying out planned activities; that AgJunction’s future results of operations will be consistent with management expectations in relation thereto; availability of key supplies, components, services, networks and developments; the impact of increasing competition; conditions in general economic, agricultural and financial markets; demand for the Company’s products; and the continuity of existing business relationships.

Since forward-looking information addresses future events and conditions, such information by its very nature involves inherent risks and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors and risks. These include, but are not limited to the risks associated with the industries in which AgJunction operates; competition; inability to introduce new technology and new products in a timely manner; legal claims for the infringement of intellectual property and other claims; negative conditions in general economic, agricultural and financial markets; and reduced demand for the Company’s products. Readers are cautioned that the foregoing list of factors is not exhaustive.

Additional information on other factors that could affect the Company’s operations or financial results, are included in reports of AgJunction on file with applicable securities regulatory authorities, including but not limited to, AgJunction’s Annual Information Form which may be accessed on its SEDAR profile at www.sedar.com. The forward-looking information contained in this press release is made as of the date hereof and AgJunction undertakes no obligation to update publicly or revise any forward-looking information, whether as a result of new information, future events or otherwise, unless so required by applicable securities laws.

Contact:

Media

[email protected]

Investor Relations

Gateway Investor Relations
Cody Slach, Managing Director
1-949-574-3860
[email protected]



II-VI Incorporated to Present at ECOC Market Focus 2020

PITTSBURGH, Dec. 02, 2020 (GLOBE NEWSWIRE) — II‐VI Incorporated (Nasdaq: IIVI), a leading provider of optical communications solutions for datacom and telecom networks, today announced that Dr. Sanjai Parthasarathi, Chief Marketing Officer, will be an invited speaker at ECOC, the annual European Conference on Optical Communications. The presentation will take place virtually during the Market Focus event on December 8 at 6:20 p.m. CET.

During the presentation, Dr. Parthasarathi will share the latest trends and insights on Compound Semiconductors and Engineered Materials Enabling Biomedical Optics. The ECOC Market Focus program is a focal point of the show, featuring presentations from leading experts in the fiber-optics community.

II-VI will also participate as a virtual exhibitor, December 7-9, and will showcase one of the broadest portfolios of optical communications products in the industry. Booth visitors will interact with company representatives and experience video demonstrations of these market-leading products, which are enabling the next generation of applications in datacom, telecom, and 3D sensing.

For more information about ECOC, or to register for a free visitor pass to the virtual exhibit hall and Market Focus panels, visit: www.ecocexhibition.com/register/.


About II-VI Incorporated

II-VI Incorporated, a global leader in engineered materials and optoelectronic components, is a vertically integrated manufacturing company that develops innovative products for diversified applications in communications, materials processing, aerospace & defense, semiconductor capital equipment, life sciences, consumer electronics, and automotive markets. Headquartered in Saxonburg, Pennsylvania, the Company has research and development, manufacturing, sales, service, and distribution facilities worldwide. The Company produces a wide variety of application-specific photonic and electronic materials and components, and deploys them in various forms, including integrated with advanced software to support our customers. For more information, please visit us at www.ii-vi.com.

CONTACT: Mark Lourie
Vice President, Corporate Communications
[email protected]
www.ii-vi.com/contact-us



Sentry Management Taps Denise Tumulty as Vice President of Corporate Marketing

Orlando, FL, Dec. 02, 2020 (GLOBE NEWSWIRE) — Sentry Management, Inc., a national leader in condominium and homeowner association management, has announced the addition of Denise Tumulty as their Vice President of Corporate Marketing. Denise will be responsible for the national marketing strategy of the company across 40 markets in 17 states, as well as internal and external communications.

“Denise brings broad marketing and branding expertise that will be a welcome addition to our leadership team as we accelerate the growth of our business and invest in top talent,” said Bradley Pomp, President of Sentry Management. “I welcome Denise to Sentry Management and am looking forward to her insights as we invest in new technology and build upon our culture of impeccable service to clients and residents across the country.”

Denise has a rich and varied background of creating successful integrated marketing campaigns, most recently as the Director of Marketing for Mount Sinai Medical Center in Miami. She started her career in Manhattan at a large media agency, negotiating and managing national TV buys and sponsorships for highly respected brands like T-Mobile. During this time, she also earned her professional MBA from Binghamton University, graduating at the top of her class. Denise’s areas of expertise include brand identity, content development, user experience, market research, and media strategy, as well as engineering lead generating social media and digital campaigns.

“I’m thrilled to join the Sentry Management team and look forward to helping accelerate continued growth throughout the nation, and reinforcing the Sentry brand as one of the nation’s top condominium and homeowner association management providers,” Denise noted.

Denise will oversee the company-wide marketing endeavors from Sentry Management’s home office in the Orlando suburb of Longwood, Florida. To learn more about Sentry Management and the regions they serve, visit SentryMgt.com.

Sentry Management is a full-service community management company. Sentry’s business is the day-to-day operation of communities, homeowner associations and condominiums. Sentry is accredited as an AMO® (Accredited Management Organization) by the Institute of Real Estate Management, providing independent evaluation that Sentry has one of the highest operating and financial standards in the industry. Sentry operates in dozens of localities in Florida, Arizona, Colorado, Connecticut, Georgia, Idaho, Iowa, Indiana, Kansas, Maryland, Missouri, New Mexico, New York, North Carolina, South Carolina, Tennessee and Virginia.

###

Attachment



Denise Tumulty
Sentry Management Inc.
407-788-6700
[email protected]

Spero Therapeutics Announces Appointment of Tamara Joseph as Chief Legal Officer

Appointment strengthens leadership team ahead of tebipenem HBr’s potential commercialization

CAMBRIDGE, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced the appointment of Tamara Joseph, J.D., L.L.M., as Chief Legal Officer, effective as of today.

“We are thrilled to welcome Tamara to Spero and look forward to benefiting from her extensive legal and leadership experience in the biotechnology space,” said Ankit Mahadevia, M.D., Chief Executive Officer of Spero Therapeutics. “This experience will be invaluable as we work to address the growing threat of multidrug-resistant bacteria through the potential commercialization of tebipenem HBr and the advancement of SPR720 and SPR206 through clinical trials.”

Ms. Joseph brings significant experience to Spero with over 20 years of leadership roles in the biotechnology sector, overseeing legal, public and government affairs, compliance and risk management. Ms. Joseph most recently served as General Counsel at Millendo Therapeutics, Inc. and previously served as General Counsel at Enzyvant Therapeutics Ltd., InVivo Therapeutics Holdings Corp., Cubist Pharmaceuticals, Inc., Mayne Pharma Ltd., and Transkaryotic Therapies, Inc. Her experience also includes establishing and leading the ex-US operations of the Biogen Idec Inc. legal and public affairs departments. Ms. Joseph received her B.A. in economics from Duke University, her J.D. from the University of Michigan Law School and her L.L.M. degrees from the College of Europe in Belgium and the University of Paris.

Ms. Joseph commented, “Joining Spero’s management team is a truly exciting opportunity. Spero’s development pipeline is impressive, and its lead asset is on a path towards regulatory approval following the announcement of positive data from the Phase 3 ADAPT-PO trial. I look forward to working with Ankit and the team as we work to advance our pipeline and transition to a commercial organization.”

In connection with Ms. Joseph joining Spero, on November 20, 2020, the Compensation Committee of Spero’s Board of Directors approved, effective as of December 2, 2020, the grant of a non-qualified stock option award to purchase 75,000 shares of its common stock to Ms. Joseph under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended, or the 2019 Inducement Plan. The stock option was granted as an inducement material to Ms. Joseph becoming an employee of Spero in accordance with Nasdaq Listing Rule 5635(c)(4). The option has an exercise price equal to the closing price of Spero’s common stock on The Nasdaq Global Select Market on December 2, 2020. The option will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36-months, subject to Ms. Joseph’s continued employment with Spero on such vesting dates. The option is subject to the terms and conditions of the 2019 Inducement Plan and the terms and conditions of a stock option agreement covering the grant.

About Spero
Therapeutics

Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.

Spero’s lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is being developed as the first oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). In September 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP.

Spero is also advancing SPR720, its novel oral therapy product candidate being developed for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections.

Spero also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform that is being developed to treat MDR Gram-negative infections in the hospital setting.

For more information, visit https://sperotherapeutics.com.

Forward-Looking Statements

This press release may contain forward-looking statements. These statements include, but are not limited to, statements about the initiation, timing and submission to the FDA of a NDA for tebipenem HBr and the potential approval of tebipenem HBr by the FDA; future commercialization, the potential number of patients who could be treated by tebipenem HBr and market demand for tebipenem HBr generally; expected broad access across payer channels for tebipenem HBr; the expected pricing of tebipenem HBr and the anticipated shift from IV to oral administration; the design, initiation, timing, progress and results of Spero’s preclinical studies and clinical trials and its research and development programs, including the commencement of Spero’s planned Phase 2a clinical trial of SPR720 and the commencement of Spero’s planned Phase 1 bronchoalveolar lavage (BAL) clinical trial assessing the penetration of SPR206 into the pulmonary compartment and its renal impairment study of SPR206; management’s assessment of the results of such preclinical studies and clinical trials; the direct and indirect impact of the pandemic caused by an outbreak of a new strain of coronavirus on Spero’s business and operations, including manufacturing, research and development costs, clinical trials, regulatory processes and employee expenses; and Spero’s cash forecast and anticipated expenses, anticipated payments under Spero’s agreement with Everest Medicines, potential payments under Spero’s agreement with BARDA, the sufficiency of its cash resources and the availability of additional non-dilutive funding from governmental agencies beyond any initially funded awards. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intent,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including Spero’s ability to timely complete related Phase 1 trials for its planned NDA submission for tebipenem HBr, taking into account the possible effects of the COVID-19 pandemic; Spero’s need for additional funding; the lengthy, expensive, and uncertain process of clinical drug development; whether results obtained in preclinical studies and clinical trials will be indicative of results obtained in future clinical trials; Spero’s reliance on third parties to manufacture, develop, and commercialize its product candidates, if approved; the ability to develop and commercialize Spero’s product candidates, if approved; the potential impact of the COVID-19 pandemic; Spero’s ability to retain key personnel and to manage its growth; whether Spero will satisfy all of the pre-conditions to receipt of the development milestone payment under its agreement with Everest Medicines; whether BARDA elects to exercise its second option under Spero’s agreement with BARDA; whether Spero’s cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; and other factors discussed in the “Risk Factors” set forth in filings that Spero periodically makes with the U.S. Securities and Exchange Commission. The forward-looking statements included in this press release represent Spero’s views as of the date of this press release. Spero anticipates that subsequent events and developments will cause its views to change. However, while Spero may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Spero’s views as of any date subsequent to the date of this press release.

Spero Investor and Media Contact:

Sharon Klahre
Vice President, Investor Relations
857-242-1547
[email protected]